NLS Pharmaceutics Ltd.
13F holders, Q2 2025 (June 30)1holders −9
1new positions
0sold out
$2.89avg. 13F price*
At the end of Q2 2025, 1 institutions reported holding NLS Pharmaceutics Ltd. in their 13F filings, down 9 from Q2 2024. 1 opened new positions and 0 sold out. The largest holder was CoreCap Advisors, LLC ($104).
- Company
- NLS Pharmaceutics Ltd.
- CUSIP
- H57830103
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $104 |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q2 2025: 36 shares bought, net +36 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| CoreCap Advisors, LLC | 0.00% | New | 36 | $104 |
"% of holder's portfolio" is NLS PHARMACEUTICS LTD's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. the manager owns.